Lv5
1050 积分 2023-04-17 加入
Catumaxomab: First Approval
6天前
已完结
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
6天前
已关闭
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
6天前
已完结
Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement
9天前
已完结
Reducing affinity as a strategy to boost immunomodulatory antibody agonism
16天前
已完结
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
16天前
已完结
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial
1个月前
已完结
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer
1个月前
已关闭
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer
1个月前
已关闭
[2016 World Health Organization classification of tumors of the urinary tract: an update]
1个月前
已完结
皖公网安备34019202002308
